Calley Means questions the vaccine's safety and effectiveness, but a clinical trial involving more than 40,000 people found stronger protection against influenza than a standard flu shot, with no clear serious safety signal.
WASHINGTON | A former adviser to the Trump administration's Department of Health and Human Services is challenging the safety and effectiveness of Moderna's newly approved messenger RNA influenza vaccine, despite clinical trial findings showing that the shot provided greater protection against seasonal flu than a conventional vaccine without identifying a clear serious safety problem.
Calley Means, a prominent figure in the Make America Healthy Again movement and former HHS adviser, made the claims during appearances on Joe Rogan's podcast and CBS News' "Face the Nation" earlier this month.
His comments have intensified scrutiny of the new vaccine, which received Food and Drug Administration approval in August for adults 50 and older.
The controversy comes as Americans enter another influenza season and public health officials confront persistent questions about vaccine safety, government oversight and the role of newer vaccine technologies.
At the center of the dispute is a fundamental distinction between what clinical trials demonstrate and how their findings are communicated to the public.
The available evidence indicates that Moderna's mRNA flu vaccine reduced laboratory-confirmed influenza cases more effectively than a standard-dose flu vaccine. Researchers also found higher rates of temporary reactions, including injection-site pain, fatigue and headaches, but no established increase in serious adverse events.
